Stoke Therapeutics 2025 Annual Report: Key Highlights and Investor Insights

Overview

Stoke Therapeutics, Inc. (NASDAQ: STOK), a biotechnology company headquartered in Bedford, Massachusetts, has released its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This comprehensive filing provides investors with critical insights into the company’s financial health, operational performance, pipeline progress, and significant risk factors that could influence future share price movements.

Key Financial Highlights

• Public Float and Share Count: As of June 30, 2025, the aggregate market value of Stoke Therapeutics’ publicly held common equity was approximately \$592 million. As of February 28, 2026, the company reported 59,150,790 shares outstanding of its common stock.
• NASDAQ Listing: Stoke’s common stock is traded on the Nasdaq Global Select Market under the symbol “STOK.”
• SEC Compliance: The company affirms timely filing of all required reports and compliance with the Interactive Data File submissions.

Business Overview and Pipeline Updates

Stoke Therapeutics is pioneering RNA-based medicines, specifically utilizing its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to address the underlying genetic causes of severe diseases. The company’s lead asset, zorevunersen (STK-001), is being developed to treat Dravet syndrome—a rare, severe form of epilepsy. Key updates include:

• Collaboration with Biogen: Stoke maintains a collaboration agreement with Biogen International GmbH, which includes potential milestone and royalty payments. The exercise of options or achievement of milestones under this agreement could have a significant impact on Stoke’s future revenues and share price.
• Clinical Progress: Zorevunersen continues through clinical trials to demonstrate its efficacy in treating Dravet syndrome. The company is testing whether the drug can reduce seizures and improve behavioral or cognitive outcomes. Results from these studies, as well as any regulatory feedback or clinical milestones achieved, may be price-sensitive events.
• Pipeline Expansion: Stoke is leveraging its TANGO platform to develop additional candidates, including programs for ADOA, MECP2-related disorders, and SYNGAP1. Progress or setbacks in these programs could materially influence investor sentiment.
• Intellectual Property: The company’s ability to obtain, maintain, and protect its intellectual property is identified as a key driver for its competitive positioning and long-term value.

Risks and Forward-Looking Statements

The report contains several forward-looking statements, and management emphasizes that actual results may differ materially due to various risk factors. Important risks highlighted for shareholders include:

• Funding Risk: Stoke’s ability to secure sufficient funding is critical for ongoing R&D and clinical trial activities. Any challenges in raising capital or macroeconomic headwinds could impact the company’s cash runway and operations.
• Operational Risks: The company faces risks from inflation, interest rate fluctuations, supply chain disruptions, and geopolitical uncertainties. These external factors could directly or indirectly affect costs, clinical development timelines, and strategic partnerships.
• Regulatory and Clinical Risks: Delays or adverse outcomes in clinical trials, or failure to achieve positive regulatory milestones, would likely have a negative effect on share value.
• Management and Key Personnel: The ability to attract and retain experienced executives and R&D talent remains a focus for the company.
• Competitive Landscape: Developments in the competitive or regulatory landscape for genetic medicines and rare diseases could influence future market opportunities for Stoke.

Shareholder Considerations and Potential Price-Sensitive Events

• Milestone Events with Biogen: Any announcement related to option exercise, milestone payments, or royalty arrangements could drive significant share price movement.
• Clinical Results: Upcoming data releases from the zorevunersen trials or other pipeline programs, as well as regulatory submissions or designations (e.g., orphan drug status), may act as catalysts.
• Financing Activities: Additional capital raises, public offerings, or strategic partnerships could impact dilution and valuation.
• Restatement/Correction Risk: The company confirms that its financial statements do not reflect corrections of prior errors, and no restatements requiring executive compensation recovery have occurred.
• Internal Controls: Stoke has not yet filed a report on internal control effectiveness under Section 404(b) of Sarbanes-Oxley, which may warrant monitoring.

Corporate Governance and Compliance

• Stoke is not a well-known seasoned issuer, nor is it a shell or emerging growth company.
• The company is classified as an accelerated filer and a smaller reporting company.
• There are no unresolved SEC staff comments, nor disclosures related to foreign jurisdictions that prevent audit inspections.

Table of Contents and Key Sections

The report is organized into the standard 10-K sections, including Business Overview, Risk Factors, Management’s Discussion and Analysis, Financial Statements, Executive Compensation, Corporate Governance, and more.

• Key financials, risk factors, and MD&A analysis begin on page 1 and extend through page 88.
• Corporate governance, executive compensation, and related party disclosures are in Part III.

Conclusion

Stoke Therapeutics remains a clinical-stage leader in RNA-based therapies for severe genetic diseases, with its future prospects closely tied to ongoing clinical milestones, strategic collaboration with Biogen, and financial discipline. Investors should monitor upcoming trial data, partnership news, and macroeconomic developments, as these could materially influence the company’s share price in the near term.

Disclaimer: This article is a summary interpretation of Stoke Therapeutics’ 2025 Annual Report on Form 10-K and is intended for informational purposes only. It does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties; actual outcomes may differ. Investors should review the full SEC filing and consult their financial advisors prior to making investment decisions.

View Stoke Therapeutics, Inc. Historical chart here